HUTCHMED (LON:HCM) Hits New 52-Week Low – What’s Next?

HUTCHMED (China) Limited (LON:HCM) hit a new 52-week low during trading on Wednesday . The stock traded as low as GBX 170 and last traded at GBX 175, with a volume of 14706 shares. The stock had previously closed at GBX 174.

HUTCHMED Trading Down 2.0%

The company has a debt-to-equity ratio of 7.91, a current ratio of 4.96 and a quick ratio of 2.97. The firm’s 50 day moving average is GBX 199.12 and its 200 day moving average is GBX 208.63. The company has a market capitalization of £1.45 billion, a PE ratio of 3.19 and a beta of 0.45.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).